Valuation
- Market cap
- 1,952,244,000
- Revenue TTM
- $62,900,000
- Net income TTM
- $-204,630,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -325.33%
- Debt to equity
- 0.02
Trading
- Volume
- 14,830,200
- Avg volume
- 5,380,362
- Day's range
- $5.03 – $5.66
- Shares out
- 351,123,000
- Stochastic %K
- 9%
- Beta
- 1.61
- Analysts
- Strong Sell
- Price target
- $13.30
Company profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment o...
Show more
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 332 208 6102
- Website
- https://www.nuvationbio.com
- Address
- 1500 Broadway, Suite 1401, New York, United States
Latest news
No headlines yet.
